Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Predicting MM response to cellular and immunotherapies

Paola Neri • 17 May 2019
COMy 2019
Multiple Myeloma Antibodies CAR-T Checkpoint inhibitors Daratumumab

Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discusses how immune deregulation can be used to predict response to cellular therapies and immunotherapies, such as CAR T-cell products and monocloncal antibodies. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Paola Neri

1:45
Using the available repertoire of bispecific antibodies for treating multiple myeloma
Paola Neri • 17 Feb 2024
1:20
Antigen loss as a key driver of resistance to anti-BCMA T-cell therapies in myeloma
Paola Neri • 17 Feb 2024
Resistance mechanisms mediated by the microenvironment in multiple myeloma
Charlotte Pawlyn et al. • 15 Apr 2023
1:51
Optimizing immunotherapy in myeloma: tumor profiling, mutations & characterizing T-cell fitness
Paola Neri • 12 May 2023

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals